FDA grants breakthrough therapy designation to Usona Institute’s psilocybin for major depressive disorder
Breakthrough Therapy Designation establishes FDA’s organizational commitment to promoting an efficient development program for psilocybin in MDD. The designation of psilocybin as a Breakthrough Therapy for MDD acknowledges